| |
|
上田 龍三 |
愛知医科大学・教授 |
| 腫瘍免疫 |
| Strategy for preventing hepatitis B reactivation in patients with resolved HBV infection following rituximab-containing chemotherapy. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Hepatology.; 60(2):765-6, 2014. |
| HTLV-1 bZIP factor-specific CD4 T cell responses in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantationJ Immunol, Narita T, Ishida T, Masaki A, Suzuki S, Ito A, Mori F, Yamada T, Ri M, Kusumoto S, Komatsu H, Miyazaki Y, Takatsuka Y, Utsunomiya A, Niimi A, Iida S, Ueda R. J Immunol. 192(3):940-7. 2014. |
| Multicenter phase II study of Mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M Ueda R: J Clin Oncol. 32(11):1157-63, 2014 |
|
| |
|
北川 雄光 |
慶應義塾大学外科・教授 |
| 外科 |
Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W, Tomita N, Nakagoe T, Shimada M, Sugihara K, Mori M. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg 260(2): 259-66, 2014.08
|
| Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol. 31(29): 3704-10, 2013.10 |
| Takeuchi H, Kitagawa Y. New Sentinel Node Mapping Technologies for Early Gastric Cancer. Annals of Surgical Oncology 20(2): 522-532, 2013.02 |
|
| |
|
小西 郁生 |
京都大学大学院医学研究科 器官外科学講座
婦人科学産科学分野・教授
|
| 産科婦人科学（婦人科腫瘍学） |
(1) Peng J, Yoshioka Y, Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J, Kharma B, Murakami R, Abiko K, Murphy SK, Konishi I.
The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-a potential therapeutic target.
Mol Carcinog. 2015 Feb 7. [Epub ahead of print]
|
(2) Matsumoto K, Katsumata N, Shibata T, Satoh T, Saitou M, Yunokawa M, Takano T, Nakamura K, Kamura T, Konishi I.
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Gynecol Oncol. 2015 Feb;136(2):218-23.
|
(3) Kharma B, Baba T, Matsumura N, Kang HS, Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe Y, Yoshioka Y, Murphy SK, Mandai M, Hunstman DG, Konishi I.
STAT1 drives tumor progression in serous papillary endometrial cancer.
Cancer Res. 2014 Nov 15;74(22):6519-30.
|
|
| |
|
小松 浩子 |
慶應義塾大学看護学部・教授、同大学院健康マネジメント研究科・教授 |
| がん看護学、緩和ケア |
| Yagasaki K, Komatsu H, Inner conflict in patients receiving oral anticancer agents: a qualitative study, BMJ Open (in press). |
| Komatsu H, Yagasaki K. The Power of nursing: Guiding patients through a journey of Uncertainty. European Journal of Oncology Nursing. 2014, doi:10.1016/j.ejon.2014.03.006. |
| Komatsu H, Yagasaki K, Shoda R, Chung Y, Iwata T, Sugiyama J, Fujii T. Repair of the threatened feminine identity: experience of women with cervical cancer undergoing fertility preservation surgery. Cancer Nursing, 2014, 37(1), 75-82. |
|
| |
|
関原 健夫 |
(公財)日本対がん協会常務理事 |
| 対がん活動（がん啓蒙、がん患者相談・支援等） |
| 闘病記「がん六回 人生全快」（2001年：朝日新聞社、2009年：講談社） |
|
| |
|
祖父江 友孝 |
大阪大学大学院医学系研究科教授 |
| がん疫学 |
| Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S. Int J Cancer. 2002; 99: 245-251. |
| Screening for lung cancer with low-dose helical computed tomography: Anti-Lung Cancer Association Project. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, Nishiyama H, Matsui E, Eguchi K. J Clin Oncol. 2002; 20: 911-20. |
| A case-control study for evaluating lung-cancer screening in Japan. Sobue T, Suzuki T, Naruke T. Int J Cancer. 1992; 50:230-7. |
|
| |
|
原 純一 |
大阪市立総合医療センター副院長 |
| 小児腫瘍学 |
Hara J. Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol. 2012 Jun;17(3):196-203
|
| Sawada A, Takihara Y, Kim JY, Matsuda-Hashii Y, Tokimasa S, Fujisaki H, Kubota K, Endo H, Onodera T, Ohta H, Ozono K, Hara J. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest. 2003 Dec; 112(11): 1707-13. |
| Hara J, Benedict SH, Yumura K, Ha-Kawa K, Gelfand EW: Rearrangement of variable region T cell receptor gamma genes in acute lymphoblastic leukemia. V gamma gene usage differs in mature and immature T cells. J Clin Invest 1989;83(4):1277-1283 |
|
| |
|
堀田 知光 |
国立がん研究センター 理事長・総長 |
| 血液腫瘍内科 |
Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin’s Lymphoma: JCOG 0203 Trial
Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T and Hotta T
J Clinical Oncol 29(30):3990-3998, Oct 2011
|
Phase II Study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the japan Clinical Oncology Group Study, JCOG9508
Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Shimoyama M, Ogura M and Hotta T
Intl J of Hematology 96:74-83, Jun 2012
|
Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies
Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T and Tobinai K
Cancer Science 103(7):1290-1295, Jul 2012
|
|
| ○ |
|
門田 守人 |
がん研有明病院・病院長 |
| 消化器外科 |
| Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Ritchie SA1, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, Monden M, et al. BMC Cancer. 2013 Sep 12;13:416. |
| 5-fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E; FAIT Research Group. Hepatol Res. 2012 Feb;42(2):150-65. |
| Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, Sakamoto M, Takayasu K, Makuuchi M, Matsuyama Y, Monden M; Liver Cancer Study Group of Japan. Br J Surg. 2011 Apr;98(4):552-7. |
|
